Results 231 to 240 of about 3,289,248 (326)

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Mineralocorticoid receptor antagonists (MRAs) are crucial in managing cardiovascular diseases, with different MRAs demonstrating varying efficacy across diverse disease contexts. This research aims to compare the cardiovascular protective effects of different MRAs across various disease conditions.
Jiao Wang   +4 more
wiley   +1 more source

Short report: Hospitalization for new‐onset heart failure in survivors of hospitalized COVID‐19

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Previous studies have reported an incidence of new‐onset heart failure (HF) among COVID‐19 survivors ranging from 0.7 to 8.5 per 100 person‐years, but they relied on administrative data for outcome ascertainment. Given the public health implications, a more accurate characterization of the HF burden post‐COVID‐19 is important. Methods and
Vicente Corrales‐Medina   +6 more
wiley   +1 more source

Arrhythmic Mitral Valve Prolapse and Sudden Cardiac Death

open access: yesCirculation, 2015
C. Basso   +15 more
semanticscholar   +1 more source

Angiotensin receptor‐neprilysin inhibitors in concurrent heart failure with reduced ejection fraction and kidney failure

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Angiotensin receptor‐neprilysin inhibitor (ARNI) therapy has demonstrated improved outcomes in heart failure with reduced ejection fraction (HFrEF). However, its benefits in patients with concomitant kidney failure undergoing replacement therapy remain uncertain. Methods and results Using the National Health Insurance Service database, we
Mi‐Hyang Jung   +8 more
wiley   +1 more source

Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
Baseline characteristics for the vericiguat global study in participants with chronic heart failure (VICTOR) trial. ARNI, angiotensin receptor/neprilysin inhibitor; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; GDMT, guideline‐directed medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection ...
Clara I. Saldarriaga   +21 more
wiley   +1 more source

A case of Hyperkalemia-induced Brugada Phenocopy: a rare but serious electrocardiographic imposter. [PDF]

open access: yesOxf Med Case Reports
Rezkalla A   +5 more
europepmc   +1 more source

Kidney status and events preceding death in heart failure: A real‐world nationwide study

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Aims Chronic kidney disease is a frequent comorbidity in heart failure (HF) patients, affecting prognosis and mortality. This study investigates the relationship between kidney function and adverse kidney events preceding death in HF patients. Methods and results We analysed registry data of HF patients who died between 2014 and 2021, with at ...
Deewa Zahir Anjum   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy